Cargando…

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal o...

Descripción completa

Detalles Bibliográficos
Autores principales: Braña, Ignacio, Pardo, Estefanía, Burger, Stefanie, González del Pozo, Pablo, Alperi, Mercedes, Queiro, Rubén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861177/
https://www.ncbi.nlm.nih.gov/pubmed/36675395
http://dx.doi.org/10.3390/jcm12020467
_version_ 1784874776497487872
author Braña, Ignacio
Pardo, Estefanía
Burger, Stefanie
González del Pozo, Pablo
Alperi, Mercedes
Queiro, Rubén
author_facet Braña, Ignacio
Pardo, Estefanía
Burger, Stefanie
González del Pozo, Pablo
Alperi, Mercedes
Queiro, Rubén
author_sort Braña, Ignacio
collection PubMed
description Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal observational single-center study of all patients with PsA who had received at least one dose of IXE. Adverse events (AEs) and drug retention rate were the main study focus. Survival was analyzed using Kaplan–Meier curves and predictive factors using multivariate Cox regression analysis. The hazard ratio (HR) was used as a measure of the association. Results: Seventy-two patients were included (52 women and 20 men). Median disease duration was 5 years (IQR 3–9). More than 90% received ≥2 biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) prior to IXE. Ixekizumab showed a 1-year retention rate of 65% and a 2-year retention rate of 57%. Regarding discontinuation due to AEs, 0.18 AEs per person-year were identified. The number of previous biologics did not influence drug survival but prior use of methotrexate (HR 2.31 (95% CI 1.05–5.10), p < 0.05) and depression (HR 2.40 (95% CI 1.07–5.41), p < 0.05) increased the risk of IXE discontinuation. Conclusions: Ixekizumab showed a good retention rate in a PsA population mostly refractory to biologic and targeted synthetic DMARDs. Drug survival was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies. This information may be of interest to better position this drug in the PsA treatment algorithms.
format Online
Article
Text
id pubmed-9861177
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98611772023-01-22 Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience Braña, Ignacio Pardo, Estefanía Burger, Stefanie González del Pozo, Pablo Alperi, Mercedes Queiro, Rubén J Clin Med Article Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal observational single-center study of all patients with PsA who had received at least one dose of IXE. Adverse events (AEs) and drug retention rate were the main study focus. Survival was analyzed using Kaplan–Meier curves and predictive factors using multivariate Cox regression analysis. The hazard ratio (HR) was used as a measure of the association. Results: Seventy-two patients were included (52 women and 20 men). Median disease duration was 5 years (IQR 3–9). More than 90% received ≥2 biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) prior to IXE. Ixekizumab showed a 1-year retention rate of 65% and a 2-year retention rate of 57%. Regarding discontinuation due to AEs, 0.18 AEs per person-year were identified. The number of previous biologics did not influence drug survival but prior use of methotrexate (HR 2.31 (95% CI 1.05–5.10), p < 0.05) and depression (HR 2.40 (95% CI 1.07–5.41), p < 0.05) increased the risk of IXE discontinuation. Conclusions: Ixekizumab showed a good retention rate in a PsA population mostly refractory to biologic and targeted synthetic DMARDs. Drug survival was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies. This information may be of interest to better position this drug in the PsA treatment algorithms. MDPI 2023-01-06 /pmc/articles/PMC9861177/ /pubmed/36675395 http://dx.doi.org/10.3390/jcm12020467 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Braña, Ignacio
Pardo, Estefanía
Burger, Stefanie
González del Pozo, Pablo
Alperi, Mercedes
Queiro, Rubén
Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title_full Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title_fullStr Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title_full_unstemmed Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title_short Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
title_sort treatment retention and safety of ixekizumab in psoriatic arthritis: a real life single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861177/
https://www.ncbi.nlm.nih.gov/pubmed/36675395
http://dx.doi.org/10.3390/jcm12020467
work_keys_str_mv AT branaignacio treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience
AT pardoestefania treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience
AT burgerstefanie treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience
AT gonzalezdelpozopablo treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience
AT alperimercedes treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience
AT queiroruben treatmentretentionandsafetyofixekizumabinpsoriaticarthritisareallifesinglecenterexperience